Desensitization pattern of cardiac beta-adrenoceptor subtypes by prolonged in vivo infusion of pindolol and celiprolol in rats (scientific article published on 01 January 1990)

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Q27860958

Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes

Q34714173

The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat.

Q35886829

The additional properties of beta adrenoceptor blocking drugs

Q38166344

??- and ??-Adrenergic Receptor Subtypes Properties, Distribution and Regulation

Q40080146

Classification and quantitation of β-adrenergic receptor subtypes

Q40121089

Pindolol--the pharmacology of a partial agonist

Q40335577

Effects of pindolol and propranolol on beta adrenergic receptors on human lymphocytes

Q41782149

Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol

Q42202186

Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis

Q42447542

A different desensitization pattern of cardiac beta-adrenoceptor subtypes by prolonged in vivo infusion of isoprenaline

Q42490023

The role of endogenous noradrenaline in the beta-blocker withdrawal phenomenon--studies with cultured heart cells

Q42504080

Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity

Q44390290

The role of a low beta 1-adrenoceptor selectivity of [3H]CGP-12177 for resolving subtype-selectivity of competitive ligands

Q46097617

Cardiac ventricular beta 2-adrenoceptors in guinea-pigs and rats are localized on the coronary endothelium.

Q46570146

CGP 20712 A: a useful tool for quantitating beta 1- and beta 2-adrenoceptors

Q48288283

Quantitative analysis of the selectivity of radioligands for subtypes of beta adrenergic receptors.

Q52638602

Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists.

Q55487988

Beta adrenergic receptor subtypes in the atria: evidence for close coupling of beta-1 and beta-2 adrenergic receptors to adenylate cyclase

Q69885936

[The beta 2-pseudoselectivity of ISA (intrinsic sympathomimetic action)--consequences for differential therapy with beta-blockers with and without ISA?]

Q69913349

The β-Adrenergic Blockade Withdrawal Phenomenon

Q72695766

Selective desensitization of cardiac beta adrenoceptors by prolonged in vivo infusion of catecholamines in rats

Q72933156

P433

issue

P921

main subject

desensitization

Q2700499

P304

page(s)

88-95

P577

publication date

1990-01-01

P1433

published in

Basic Research in Cardiology

Q2453360

P1476

title

Desensitization pattern of cardiac beta-adrenoceptor subtypes by prolonged in vivo infusion of pindolol and celiprolol in rats

P478

volume

Reverse relations

cites work (P2860)

Q40624637	A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease
Q50917475	Agonist-induced desensitization of human β3-adrenoceptors expressed in human embryonic kidney cells.
Q67522240	Celiprolol exerts microvascular dilatation by activation of beta 2-adrenoceptors
Q40953069	Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris
Q36676469	Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease